Medical Device Network on MSN
Novocure receives CE mark for Optune Pax device
The decision was based on findings from the Phase III PANOVA-3 clinical trial.
Add Yahoo as a preferred source to see more of our stories on Google. The PANOVA-3 trial enrolled 571 patients with locally advanced pancreatic cancer. Credit: sasirin pamai/Shutterstock.com. Novocure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results